Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 17/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960123 | 0.89 | HSD17B3 (0.42) | HSD17B3AVPR2AVPR1AOXTR | |
| SCHEMBL2960705 | 0.89 | HSD17B3 (0.43) | HSD17B3AVPR2AVPR1ABRS3OXTR | |
| SCHEMBL2961925 | 0.86 | HSD17B3 (0.40) | HSD17B3AVPR2AVPR1A | |
| SCHEMBL2954169 | 0.84 | AVPR2 (0.40) | HSD17B3AVPR2AVPR1A | |
| SCHEMBL2957675 | 0.83 | AVPR2 (0.39) | HSD17B3AVPR2AVPR1AOXTR | |
| SCHEMBL2951582 | 0.83 | HSD17B3 (0.42) | HSD17B3AVPR2AVPR1AOXTR | |
| SCHEMBL2957843 | 0.83 | MMP1 (0.45) | AVPR2AVPR1A | |
| SCHEMBL2954333 | 0.81 | HSD17B3 (0.41) | HSD17B3AVPR2AVPR1AOXTR | |
| SCHEMBL2954220 | 0.78 | AVPR2 (0.39) | HSD17B3AVPR2 | |
| SCHEMBL2960127 | 0.77 | AVPR2 (0.42) | HSD17B3AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763605-B2 | [1,4]benzodiazepines as vasopressin V2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-27 | — | — | US | disclosed |
| EP-1809296-A4 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1809296-A2 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060116367-A1 | Novel [1,4]benzodiazepines as vasopressin V2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006049984-A2 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116367-A1 | Novel [1,4]benzodiazepines as vasopressin V2 receptor antagonists | AVPR2, AVPR1B, AVPR1A | HSD17B3 330/4885AVPR2 1/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.